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Abstract
Background: Clinical studies have shown that rose hip powder (RHP) alleviates osteoarthritis (OA). This might be
due to anti-inflammatory and cartilage-protective properties of the complete RHP or specific constituents of RHP.
Cellular systems (macrophages, peripheral blood leukocytes and chondrocytes), which respond to inflammatory
and OA-inducing stimuli, are used as in vitro surrogates to evaluate the possible pain-relief and disease-modifying
effects of RHP.
Methods: (1) Inflammatory processes were induced in RAW264.7 cells or human peripheral blood leukocytes (PBL)
with LPS. Inflammatory mediators (nitric oxide (NO), prostaglandin E2 (PGE2) and cytokines/chemokines) were
determined by the Griess reaction, EIA and multiplex ELISA, respectively. Gene expression was quantified by RT-
PCR. RHP or its constituent galactolipid, GLGPG (galactolipid (2S)-1, 2-di-O-[(9Z,1 2 Z,1 5 Z)-octadeca-9, 12, 15-
trienoyl]-3-O-b-D-galactopyranosyl glycerol), were added at various concentrations and the effects on biochemical
and molecular parameters were evaluated. (2) SW1353 chondrosarcoma cells and primary human knee articular
chondrocytes (NHAC-kn) were treated with interleukin (IL)-1b to induce in vitro processes similar to those occurring
during in vivo degradation of cartilage. Biomarkers related to OA (NO, PGE2, cytokines, chemokines,
metalloproteinases) were measured by multiplex ELISA and gene expression analysis in chondrocytes. We
investigated the modulation of these events by RHP and GLGPG.
Results: In macrophages and PBL, RHP and GLGPG inhibited NO and PGE2 production and reduced the secretion of
cytokines (TNF-a,I F N - g, IL-1b, IL-6, IL-12) and chemokines (CCL5/RANTES, CXCL10/IP-10). In SW1353 cells and primary
chondrocytes, RHP and GLGPG diminished catabolic gene expression and inflammatory protein secretion as shown by
lower mRNA levels of matrix metalloproteinases (MMP-1, MMP-3, MMP-13), aggrecanase (ADAMTS-4), macrophage
inflammatory protein (MIP-2, MIP-3a), CCL5/RANTES, CXCL10/IP-10, IL-8, IL-1a and IL-6. The effects of GLGPG were
weaker than those of RHP, which presumably contains other chondro-protective substances besides GLGPG.
Conclusions: RHP and GLGPG attenuate inflammatory responses in different cellular systems (macrophages, PBLs
and chondrocytes). The effects on cytokine production and MMP expression indicate that RHP and its constituent
GLGPG down-regulate catabolic processes associated with osteoarthritis (OA) or rheumatoid arthritis (RA). These
data provide a molecular and biochemical basis for cartilage protection provided by RHP.
Background
A primary feature of arthritis, in particular osteoarthritis
(OA), is the degradation and erosion of the extracellular
matrix (ECM) in cartilage. The preceding alterations of
collagen and proteoglycan implicate the activation of
enzymatic systems, i.e. matrix metalloproteinase (MMPs)
and aggrecanase (e.g. a disintegrin and metalloproteinase
with thrombospondin type I motif, ADAMTS) [1,2]. Speci-
fically, MMP-1, MMP-3 and MMP-13 cleave ECM col-
lagen [3-5]. Interleukin (IL)-1b is considered a key
catabolic factor that induces ECM degradation (reviewed
in [6]). IL-1b has multiple effects on the expression of
chondrocyte genes and affects matrix enzymes, chemo-
kines and cytokines. Some of these effects are opposed by
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phogenic protein (BMP)-2 [7]. Nitric oxide (NO) has been
identified as another agent in OA (reviewed in [8,9]): the
expression of inducible nitric oxide synthase (iNOS) and
the production of NO correlate with patho-physiological
changes in chondrocytes [10-13]. The importance of che-
mokines in OA was highlighted by the observation that
numerous chemokines and their receptors were massively
induced by IL-1b in chondrocytes [7,14-16]. This under-
scores the importance of cell recruitment during inflam-
matory processes in OA.
Natural substances may attenuate the onset and pro-
gression of OA. Clinical studies have demonstrated a ben-
eficial effect of rose hip powder (RHP) in the treatment of
OA [17-19] (for reviews see [20,21]). The underlying
bioactive constituents of RHP remain elusive, although its
known constituents such as ascorbic acid, polyphenols, fla-
vonoids and unsaturated fatty acids presumably contribute
to alleviate OA. More specifically, GLGPG, a galactolipid
isolated from RHP, inhibited chemotaxis of neutrophils
[17,18]. Also, RHP extracts and unsaturated fatty acids
thereof inhibited cyclooxygenase (COX)-1 and COX-2
activity [22,23] and could partially account for the efficacy
of RHP in the treatment of OA. Yet, RHP and/or its con-
stituents have not been directly tested in chondrocytes. In
this study, the effects of RHP and one of its constituent
galactolipid, GLGPG, have been evaluated on (1) the pro-
duction of inflammatory mediators by macrophages and
peripheral blood leukocytes, and (2) anabolic and catabolic
processes in chondrocytes.
Methods
Reagents
RHP, prepared from dried Rosa canina fruits of a selected
cultivar, was obtained from Hyben Vital, Langeland, Den-
mark. GLGPG (galactolipid (2S)-1, 2-di-O-[(9Z,1 2 Z,
15Z)-octadeca-9, 12, 15-trienoyl]-3-O-b-D-galactopyrano-
syl glycerol, abbreviated as GOPO in [18]) was isolated
from a lipophilic extract prepared from leaves of Valeri-
ana locusta or from RHP (performed by AnalytiCon Dis-
covery, Potsdam, Germany). Compounds were dissolved
in DMSO and added to the culture medium concomi-
tantly with the stimulating agent. Final DMSO concentra-
tion in culture medium in all treatments .was 0.5%. E. coli
LPS (serotype 055:B5) and fetal bovine serum (FBS) were
from Sigma (Saint-Louis, MO). RPMI 1640, DMEM, 2-
mercaptoethanol and MEM non-essential amino acids
(NEAA) were from Invitrogen (Carlsbad, CA). Human IL-
1b and recombinant interferon-g (IFN-g)w e r ef r o m
PeproTech EC (London, UK).
Cell culture
Murine RAW264.7 macrophage cells were from ATCC
(Manassas, VA) and cultured in DMEM supplemented
with 50 U/mL penicillin, 50 μg/mL streptomycin, 0.1
mM NEAA (DMEM-C) and 10% FBS. Cells were seeded
into 12-well or 96-well plates at 1 and 0.05 × 10
6 cells
per well, respectively, and used after 2 days of pre-cul-
ture. Cells were starved for 18 h in DMEM-C containing
0.25% FBS before the start of treatment and stimulated
with LPS (1 μg/mL) for 4-24 h in phenol red-free
DMEM-C containing 0.25% FBS.
Peripheral blood leukocytes (PBL) were obtained from
healthy male and female donors (Blood Donor Service,
University Hospital, Basel, Switzerland). Human primary
cell protocols were approved by the Swiss Federal Office
of Public Health (No. A050573/2 to J. Schwager). Ery-
throcytes were removed by the Dextran sedimentation
procedure [24]. Cell viability was determined by the
Trypan Blue exclusion test and exceeded 95%. PBL (at
3-8 × 10
6 cells/mL) were cultured in phenol-red free
RPMI 1640, supplemented with 0.25% FBS, 0.1 mM
NEAA, 50 U/mL penicillin, 50 μg/mL streptomycin and
5×1 0
-5 M 2-mercaptoethanol. Cells were stimulated
with LPS (100 ng/mL) and IFN-g (20 U/mL) for 2-24 h.
SW1353 chondrosarcoma cells were from ATCC and
cultured in DMEM-C containing 10% FBS. Cells were
seeded into 6-well plates at 0.5 × 10
6 cells per well.
Sub-confluent cell monolayers were washed and incu-
bated overnight in DMEM-C containing 0.25% FBS and
0.2% lactalbumin hydrolysate (Bacto™ LC, Becton Dick-
inson, Franklin Lakes, NJ). Cells were activated with 10
ng/mL IL-1b in phenol-red free DMEM-C supplemen-
ted with 0.25% FBS and 0.2% lactalbumin hydrolysate in
t h ep r e s e n c eo fi n c r e a s i n gc oncentrations of test com-
pounds for 4-24 h. Batches of normal human articular
chondrocytes from knee (NHAC-kn) obtained from dif-
ferent individuals were from Lonza and cultured in
chondrocyte growth medium (Lonza, Wakersville, MD).
For experiments NHAC-kn were used at passage 3 to 6.
Cells were seeded into 6-well plates at 0.5 × 10
6 cells
per well and activated with IL-1b (10 ng/mL) for 4-24 h.
Cells were lysed in RLT buffer (Qiagen) after 2-4 h of
culture and total RNA was extracted. Culture superna-
tants were harvested after 24 h of culture and stored at
-80°C until use for analysis.
RNA isolation, cDNA synthesis and RT-PCR
Total RNA was isolated using the RNeasy Mini Kits
(Qiagen, Hilden, Germany) as previously described [25].
RNA quality and quantity was assessed by Nanodrop
®
ND-1000 and evaluated by the ND-1000 3.2.1 software
(Witec AG, Littau, Switzerland).
Total RNA was transcribed into first strand cDNA
using the Superscript™ First-Strand Synthesis System
for RT-PCR from Invitrogen (Carlsbad, CA) [25]. Real-
time PCR analysis was performed using the ABI
PRISM
® 7700 Sequence Detection System or the ABI
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tems [ABI], Foster City, CA). Primers and probes were
designed with the Primer Express™ software purchased
from ABI. PCR was performed using the Taqman
® uni-
versal PCR Master Mix (ABI). 18S rRNA primers and
probes were used as internal standards. Relative gene
expression quantification was performed by subtracting
threshold cycles (CT) for ribosomal RNA from the CT of
the targeted gene (ΔCT). Relative mRNA levels were
then calculated as 2
-ΔΔCT,w h e r eΔΔCT refers to the
ΔCT of unstimulated minus treated cells. The values
were obtained from at least three independent series of
experiments, in which each treatment was performed in
duplicate with each being analyzed twice in RT-PCR.
Multiparametric analysis of cytokines, chemokines and
interleukins
Multiparametric kits were obtained from BIO-RAD
Laboratories (Hercules, CA) and used in the LiquiChip
Workstation IS 200 (Qiagen, Hilden, Germany). The
data were evaluated with the LiquiChip Analyser soft-
ware (Qiagen). In all experimental series, the proteins
secreted into the culture supernatants were determined.
Measurement of nitric oxide and PGE2 determination
The concentration of NO in culture supernatants was
measured using the Griess Reaction [26]. Secreted PGE2
was determined by Enzyme Immuno Assay (EIA) (Cay-
man Chemicals, Ann Harbor, WI).
Statistical analysis
Data were obtained from at least three independent ser-
ies of experiments and presented as means +/- SD (in
ELISA). p values < 0.05 (calculated by Student’s t test or
one way ANOVA) were considered statistically
significant.
Results
Rose hip and GLGPG inhibit the production of
inflammatory mediators by murine macrophages
Macrophages represent a cellular model to identify
effects of substances on inflammatory processes includ-
ing those associated with arthritis. RAW264.7 cells
responded to LPS-stimulation by producing inflamma-
tory mediators (e.g.N Oa n dP G E 2). In unstimulated
cells, test substances alone did not modulate the secre-
tion of inflammatory mediators. In LPS-treated cells,
RHP reduced NO production and PGE2 secretion at
IC50 values of 797 mg/L and 594 mg/L, respectively
(Table 1). Similarly, GLGPG significantly inhibited the
NO production (IC50 values of 28.6 mg/L), whereas
PGE2 secretion was diminished by 14 ± 9% at 38.7 mg/L
(i.e. highest concentration tested). The data are consis-
tent with the described effects of rose hip constituents
on the activity of COX isozymes [22,23]. At the investi-
gated concentrations, RHP or GLGPG did not impair
cell viability as determined by LDH release (data not
shown).
LPS-stimulation of RAW264.7 elicited the expression
of inflammatory genes. Most (e.g.g e n e sf o rT N F - a,
COX-2, iNOS, IL-1a, CCL5/RANTES, CXCL10/IP-10)
were drastically up-regulated (Table 2 and Additional
File 1). We had determined in previous experiments
that at 2, 4 and 8 h of stimulation, LPS-responding
genes were significantly up-regulated (data not shown);
at 4 h both early- and late-responding genes were signif-
icantly expressed. At this point in time, the iNOS
mRNA levels were concentration-dependently reduced
by GLGPG and RHP (Figure 1). COX-2 mRNA levels
were not affected, but those of prostaglandin E synthase
(PGES), which converts PGH2 to PGE2, were lowered
(Table 2 and Additional File 1). Among murine cyto-
kines and chemokines, CCL5/RANTES and CXCL10/IP-
10 were robustly down-regulated by RHP and GLGPG.
The expression of MMP-9 was also significantly reduced
by RHP and less profoundly by GLGPG. Remarkably,
expression of the anti-inflammatory IL-10 was increased
by both substances. Macrophage genes encoding tran-
scription factor (TF) of the NF-B signaling pathway (i.
e.N F - B1, NF-B49, NF-Bp65, I-Ba)w e r eu p - r e g u -
lated by LPS (Table 2 and Additional file 1). RHP signif-
icantly reduced all TFs towards pre-stimulation values
or below. GLGPG had less robust effects on those fac-
tors and markedly reduced only NF-B49. Thus, the test
compounds modulated gene expression at the transcrip-
tional level via elements of the NF-B pathway.
Effect of RHP and GLGPG on peripheral blood leukocytes
Orally absorbed bioactive compounds reach target tis-
sues via the vascular system, where they might exert
effects on peripheral blood leukocytes (PBL). Therefore,
the effects of RHP and GLGPG on LPS/IFN-g -activated
PBL was investigated. The secretion of chemokines or
Table 1 Effect of RHP and GLGPG on NO and PGE2
production in RAW264.7 cells
Substance IC50 ± SEM (NO) [mg/L] IC50 ± SEM (PGE2) [mg/L]
GLGPG
a 28.6 ± 4.6 (N = 6) > 38.7
c (N = 6)
RHP
b 796.9 ± 36.9 (N = 15) 594 ± 43 (N = 14)
LPS-stimulated cells were cultured for 24 h with 31.3 - 1000 mg/L RHP, or 1.2
- 38.7 mg/L GLGPG. The concentration of NO and PGE2 was determined in
culture supernatants and the IC50 values (± SEM, standard error of the mean)
were computed. N, number of independent experimental series. At the
conditions described in Materials and Methods, unstimulated and LPS-
stimulated cells produced < 0.125 μM nitrite and 25.4 ± 1.2 μM, respectively.
aGLGPG: galactolipid (2S)-1, 2-di-O-[(9Z,1 2 Z,1 5 Z)-octadeca-9, 12, 15-trienoyl]-
3-O-b-D-galactopyranosyl glycerol; MW 774
bFrom Hyben Vital
c Highest concentration of GLGPG tested. At 38.7 mg/L GLGPG, PGE2
production was inhibited by 14 ± 9%.
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idiosyncratic pattern (Table 3; Figure 2a-b and Addi-
tional file 2). RHP significantly reduced the production
of CXCL10/IP-10 and CCL5/RANTES; the levels of
other chemokines were unaltered or only affected at the
highest tested RHP concentrations (Figure 2a). GLGPG
reduced MCP-1 and MIP-1a secretion. It did, however,
not match the effect of RHP on CXCL10/IP-10 and
CCL5/RANTES production. RHP had robust effects on
secretion levels of (pro-inflammatory) IL-12p70 and
(anti-inflammatory) IL-10, while it modulated IL-1b and
IL-6 less profoundly. This contrasted with the effects of
GLGPG, which significantly diminished IL-1b and IL-6
(Figure 2b). TNF-a and IFN-g were concentration-
dependently diminished by both RHP and GLGPG (Fig-
ure 2b, Table 3). Furthermore, in PBL RHP increased
the expression of GM-CSF, an anabolic factor for chon-
drocytes [27]. Next, expression levels of inflammatory
mediators were determined in human PBL. In most
cases, RHP and GLGPG exerted effects on mRNA levels
that paralleled those described for the secreted proteins
(Table 4, Figure 2c and Additional file 3). In particular,
RHP robustly down-regulated mRNA levels of IL-1a,
TNF- a and CXCL10/IP-10, but not those of e.g.I L - 6 ,
CCL5/RANTES, COX-2, MIP-2 or MIP-3a. Other genes
that are involved in the production of eicosanoids (e.g.
5-lipoxygenase) or participate in ECM remodeling (e.g.
MMP-9) were not modulated by the test compounds.
The results infer that the main effects of the natural
substances were at the transcriptional rather than the
post-transcriptional level. A notable exception was
CCL5/RANTES, where mRNA levels were barely up-
regulated by LPS/IFN-g stimulation, while the secretion
of CCL5/RANTES was impaired by the natural
substances.
Rose hip and GLGPG modulate catabolic gene expression
in chondrosarcoma SW1353 cells
The chondrosarcoma SW1353 cell line was used as a
surrogate for primary chondrocytes. In response to exo-
genous IL-1b, these cells altered the expression of a
similar set of genes as primary chondrocytes [28]
(Tables 5 and 6). IL-1b activated SW1353 cells displayed
increases in gene expression levels of MMP-1, -3, -13
and ADAMTS-4. In contrast, MMP-2 and ADAMTS-5
were barely affected. Treatment of IL-1b-activated
SW1353 cells with RHP or GLGPG led to a significant
inhibition of gene expression of MMP-1, -3, -13 but not
of ADAMTS-4 or MMP-2 (Table 5). IL-1b treatment
only slightly influenced expression levels of anabolic
genes (i.e. aggrecan, collagen), whereas other mediators
such as COX-2, TNF-a, iNOS, IL-6 and leukemia inhi-
bitory factor (LIF) [14,29] were markedly altered by IL-
1b stimulation (see fold changes in Table 5). Basal che-
mokine gene expression was low in SW1353 cells; IL-1b
treatment induced dramatic increases of chemokine
mRNA levels, with CCL5/RANTES and MIP-3a being
the most responsive. RHP significantly decreased the
expression levels of five chemokine genes (MIP-2, MIP-
3a, IL-8, CCL5/RANTES and CXCL10/IP-10) (Table 5)
and cytokine genes including IL-1a,I L - 1 b and IL-6.
Whereas GLGPG significantly reduced CXCL10/IP-10
expression, it augmented that of MIP-2 or IL-8. This
feature was also observed with regard to anabolic genes,
Table 2 Modulation of gene expression in RAW264.7 cells by RHP and GLGPG
Gene CT
a LPS LPS + RHP (250 mg/L) LPS + GLGPG (9.7 mg/L)
fold change fold change p value
b fold change p value
b
TNF-a 22.9 29.6 21.8 0.0001 20.4 0.002
COX-2 27.5 247 203.3 0.347 217 0.660
PGES 33.0 2.2 1.6 0.0107 2.0 0.214
iNOS 29.9 197 239.4 0.041 224 0.357
IL-1a 33.7 22081 8128 0.0115 18501 0.087
IL-10 38.3 66.8 176 < 0.0001 78.6 0.074
CCL5/RANTES 29.7 515 121 < 0.0001 403 0.003
CXCL10/IP-10 27.2 342 65.4 0.0001 239 0.021
NF-B1 24.8 6.3 2.1 0.0002 6.0 0.366
NF-B49 25.3 4.1 1.5 0.0028 3.7 0.028
NF-Bp65 23.6 1.2 0.4 0.0045 1.1 0.126
I-Ba 24.4 5.5 2.0 0.0004 5.7 0.391
CD14 24.9 1.0 0.5 0.198 1.4 0.012
MMP-9 29.0 6.8 3.0 0.0493 7.8 0.145
LPS-stimulated cells were cultured with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG for 4 h and gene expression was quantified by RT-PCR. Fold changes
were calculated as indicated in Materials and Methods. Only the effects of 250 mg/L RHP and 9.7 mg/L GLGPG are shown.
aCT = cycle threshold (CT < 22 = high basal gene expression; 23 < CT < 30 = intermediate basal gene expression; CT > 30 = low basal gene expression).
bp value = significance value between (LPS)- and (LPS + compound)-treatment.
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and collagen expression. It should be stressed that the
chosen in vitro conditions preferably trigger catabolic
activity in chondrocytes, while anabolic events would
have been favored at different culture conditions.
Modulation of catabolic gene expression in primary
human articular chondrocytes
Normal human articular chondrocytes from knee
(NHAC-kn) were activated by IL-1b in the presence of
increasing concentrations of RHP or GLGPG. Basal
expression levels of the monitored genes were compar-
able in SW1353 and NHAC-kn except for ADAMTS-5,
collagen 2A1, four chemokine genes and IL-6, which
were more expressed in NHAC-kn (Tables 5 and 6).
The IL-1b induced changes in NHAC-kn gene expres-
sion levels were as marked as those observed in
SW1353 cells. IL-1b significantly up-regulated catabolic
genes (ADAMTS-4, MMP-1 and MMP-3), interleukins
(IL-1a,I L - 1 b, IL-6), chemokines (IL-8, CCL5/RANTES,
MIP-2 and MIP-3a) and COX-2 (Table 6). LIF experi-
enced strong up-regulation by IL-1b, a feature that was
not shared by the receptor for IL-1 (IL-1RI) and IL-1
receptor antagonist (IL-1Ra). The patho-physiological
stimulus (i.e.I L - 1 b) weakly affected anabolic genes like
collagen 1, collagen 2 and aggrecan (Table 6).
RHP significantly diminished the expression level of
MMP-1, MMP-3, MMP-9 and MMP-13, but had only
moderate effects on ADAMTS-4, TIMP-1 or ADAMTS-
5 (Table 6). Similarly, MIP-2, MIP-3a,C C L 5 / R A N T E S
and IL-8 were down-regulated by up to 75%. The effects
on IL-1b, IL-1RI, and IL-6 were also statistically signifi-
cant. In contrast, GLGPG weakly influenced mRNA
levels of most of the tested genes (p value ~0.1). The
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Figure 1 Effect of RHP and GLGPG on gene expression in RAW264.7 cells. Expression levels of COX-2, iNOS, CCL5/RANTES and CXCL10/IP-
10 in RAW264.7 cells stimulated with LPS for 4 h in the presence of 1.2 - 38.7 mg/L (i.e 1.25 -50 μmol/L) of GLGPG (upper panels) or 31.3 - 1000
mg/L RHP (lower panels). Relative gene expression refers to 2
-ΔΔCT (see Materials and Methods). Filled symbols on the y-axis indicate the values
observed in LPS-stimulated cells (without test substances). * p < 0.05.
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(Figure 3). It should be noted that RHP had more
potent effects on gene expression in NHAC-kn than in
PBL (Figure 2). Anabolic genes were barely altered at 4
h of IL-1b stimulation.
Distinct reactivity of different cell types to RHP and
GLGPG
Murine macrophages, human PBLs and chondrocytes
revealed idiosyncratic patterns of reactivity to RHP and
GLGPG as exemplified for IL-1a and CCL5/RANTES
(Figure 4). Treatment of cells with LPS and IL-1b,
respectively, elicited tissue-specific responses; IL-1a was
induced in all three cell populations. Concomitantly, the
effect of test compounds was robust with RHP being
more potent than GLGPG. Conversely, CCL5/RANTES
induction was strong in RAW264.7 cells and NHAC-kn
but virtually absent in PBL. In general, RHP and
GLGPG had effects on genes that were strongly acti-
vated by IL-1b or LPS; conversely, non-induced genes
were virtually unaffected.
Discussion
In this study, a panel of biological properties of rose hip
powder and its constituent galactolipids, GLGPG, has
been described for the first time and provides evidence
that cellular parameters related to cartilage destruction
and inflammatory responses were modulated by these
natural compounds. This feature has been established
using two approaches: (1) effects on inflammatory pro-
cesses including cytokines and chemokines were moni-
tored in macrophages and peripheral blood leukocytes,
(2) modulation of catabolic activity and the production
of chemokines and cytokines were determined in
SW1353 cells and NHAC-kn in vitro.
An adequate homeostasis between anabolic and cata-
bolic events ensures tissue rebuilding and renewal in
intact cartilage [1]. Growth factors including insulin-
growth factors, connective-tissue growth factors, TGF-b
or BMP favor proliferation and differentiation of chon-
drocytes and the synthesis of collagen and aggrecan.
Conversely, inflammatory factors (e.g.p r o - i n f l a m m a t o r y
interleukins, eicosanoids and nitric oxide) and protei-
nases (e.g. MMPs and ADAMTS) induce tissue erosion
and degrade ECM components, respectively. MMP-1
and -13 preferably cleave type II collagen [4]. MMP-3
has broader substrate specificity; ADAMTS-4 and -5
cleave proteoglycans [30]. IL-1b is the most important
inducer of catabolic processes in OA. TNF-a,I L - 6a n d
LIF also contribute to tissue erosion in advanced stages
of OA, although their implication in rheumatoid arthri-
tis (RA) prevails [31]. IL-1b activated primary chondro-
cytes express catabolic factors that degrade the ECM.
OA chondrocytes were rather refractory to the patho-
physiological trigger [7,32]. Here, we show that RHP
and GLGPG impaired IL-1 expression in macrophages,
leukocytes and chondrocytes. LIF, which is also involved
in OA [14,28,29], was reduced by RHP and GLGPG.
The data suggest that the substances exert their effects
at an early phase of OA development and target differ-
ent cell populations. Admittedly, this hypothesis needs
to be tested in appropriate preclinical models.
While IL-6 is of key importance in RA, it is also
involved in OA [33-36]. RHP inhibited IL-6 gene
Table 3 Effect of RHP and GLGPG on the production of chemokines and cytokines in human PBL
Protein Ratio
a LPS/IFN-g LPS/IFN-g + RHP (250 mg/L) LPS/IFN-g + GLGPG (9.7 mg/L)
pg/mL ± SD pg/mL ± SD p value
b pg/mL ± SD p value
b
Eotaxin 28 84 ± 2 62 ± 6 0.037 62 ± 3 0.013
MCP-1 497 2940 ± 226 4990 ± 71 0.007 1880 ± 368 0.074
MIP-1b 169 90900 ± 1838 109009 ± 1823 0.005 47550 ± 3465 0.004
MIP-1a 2092 21079 ± 1131 27510 ± 849 0.023 10950 ± 71 0.006
IL-8 794 325103 ± 12738 433040 ± 122728 0.059 267052 ± 36770 0.255
CCL5/RANTES 14 4470 ± 57 1011 ± 55 < 0.001 3210 ± 750 0.067
CXCL10/IP-10 47 12650 ± 16 150 ± 16 0.002 5025 ± 148 0.005
IL-1b > 2000 21900 ± 2121 14350 ± 1344 0.051 9195 ± 106 0.014
IL-6 > 2000 79650 ± 4031 68450 ± 4031 0.083 38604 ± 2828 0.005
IL-12(p70) > 200 295 ± 2 19 ± 2 0.002 69 ± 17 0.006
IL-10 67 233 ± 8 382 ± 3 0.002 143 ± 47 0.118
TNF-a > 2000 21107 ± 990 6595 ± 290 0.003 5105 ± 1775 0.008
IFN-g 672 2065 ± 106 226 ± 18 0.002 475 ± 2 0.002
GM-CSF 158 148 ± 5 190 ± 47 0.329 54 ± 2 0.002
LPS/IFN-g -stimulated cells were cultured with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG for 24 h and proteins were quantified by multiparametric
analysis (see Materials and Methods). Only the effects of 250 mg/L RHP and 9.7 mg/L GLGPG are shown.
a protein secreted by stimulated/protein secreted by unstimulated cells
b p value = significance value between (LPS/IFN-g)- and (LPS/IFN-g + substance) -treatment.
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Figure 2 Effect of RHP and GLGPG on inflammatory mediators in PBL. (a) Proteins secreted by PBLs during LPS/IFN-g stimulation for 24 h
without (symbol on the y axis) or with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG. (b) Effects of RHP (250 mg/L) and GLGPG (9.7 mg/L)
on the secretion of interleukins and chemokines by LPS/IFN-g stimulated PBL that were cultured for 24 h. Asterisks indicate statistical significant
differences in comparison to LPS-stimulated cells (* p < 0.05). (c) Expression levels of interleukins (IL-1b and IL-6) and chemokines (IL-8, CXC10/
IP-10) in LPS/IFN-g stimulated PBL cultured for 2 h with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG. The symbol on the y-axis indicates
the LPS/IFN-g -induced increase in mRNA levels, in the absence of test compounds.
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Page 7 of 14expression in chondrocytes, whereas its impact on cyto-
kine production in macrophages or leukocytes was mar-
ginal. Thus, the effect of compounds was confined to
cells, where excessive IL-6 production was deleterious;
conversely, IL-6 was not modulated in peripheral blood
leukocytes where it is required for an efficient humoral
immune response. Similarly, TNF-a has multiple actions
in the pathogenesis of RA [31] and may be a
Table 4 Effect of RHP and GLGPG on gene expression in human PBL
Gene CT
a LPS/IFN-g LPS/IFN-g + RHP (250 mg/L) LPS/IFN-g + GLGPG (9.7 mg/L)
fold change fold change p value
b fold change p value
b
COX-2 22.8 8.6 8.6 0.880 6.8 0.16
TNF-a 24.9 16.1 8.9 0.004 12.4 0.04
IL-1a 27.2 17.9 11.3 0.002 16.1 0.37
IL-6 29.8 54.8 43.6 0.254 55.6 0.94
CCL5/RANTES 25.8 1.2 1.2 0.908 1.3 0.45
CXCL10/IP-10 35.5 1444 190 < 0.001 2340 0.04
MIP-2 28.6 16.8 18.7 0.577 15.6 0.66
MIP-3a 28.7 37.6 32.3 0.159 23.1 0.01
5-LOX 25.5 0.8 0.6 0.018 0.8 0.96
MMP-9 27.3 0.8 0.9 0.830 0.8 0.81
LPS/IFN-g -stimulated cells were cultured with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG for 2 h and gene expression was quantified by RT-PCR. Fold
changes were calculated as indicated in Materials and Methods. Only the effects of 250 mg/L RHP and 9.7 mg/L GLGPG are shown.
aCT = cycle threshold (CT < 25 = high basal gene expression; 25 < CT < 30 = intermediate basal gene expression; CT > 30 = low basal gene expression).
bp value = significance value between (LPS/IFN-g)- and (LPS/IFN-g + substance) -treatment
Table 5 Effect of RHP and GLGPG on gene expression in human chondrosarcoma SW1353 cells
Gene CT
a IL-1b IL-1b + RHP (250 mg/L) IL-1b + GLGPG (9.7 mg/L)
fold change fold change p value
b fold change p value
b
MMP-1 27.2 6.3 3.6 0.002 4.5 0.019
MMP-2 22.3 0.8 0.6 0.006 1.0 0.142
MMP-3 32.7 182.7 80.6 < 0.001 137.0 0.003
MMP-9 31.8 6.3 7.1 0.285 10.7 0.001
MMP-13 28.4 17.7 8.9 < 0.001 12.7 0.005
ADAMTS-4 35.3 10.7 9.8 0.136 9.6 0.026
ADAMTS-5 31.1 0.8 0.7 0.476 1.4 0.006
TIMP-1 21.2 1.4 1.2 0.195 1.9 0.007
Aggrecan 32.0 1.8 1.3 0.017 3.7 < 0.001
Collagen I 19.2 1.1 0.8 0.028 1.8 0.001
COL2A1 31.9 0.8 0.6 0.001 0.9 0.526
MIP-2 40.2 1169 474 < 0.001 1626 0.006
MIP-3a 38.5 19642 12001 < 0.001 20822 0.437
CCL5/RANTES 42.9 35920 27081 0.048 41476 0.353
IL-8 34.5 12022 5599 < 0.001 16308 0.001
CXCL10/IP-10 39.7 3274 836 0.001 1436 0.001
IL-1a 37.7 42.3 29.9 0.036 32.0 0.065
IL-1b 31.9 135.3 118.1 0.195 100.8 0.012
IL-6 38.4 10846 5969 0.001 8876 0.122
IL-1Ra 31.9 1.1 1.4 0.381 1.7 0.111
IL-1RI 27.1 1.7 0.9 0.001 1.7 0.885
TNF-a 34.5 319.2 705.1 0.001 567.8 0.003
iNOS 35.4 17.6 22.4 0.139 21.2 0.236
COX-2 34.4 23.4 19.0 0.080 35.3 0.005
LIF 30.1 64.8 53.9 0.118 42.1 0.005
IL-1b -stimulated cells were cultured with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG for 4 h and gene expression was quantified by RT-PCR. Fold
changes were calculated as indicated in Materials and Methods. Only the effects of 250 mg/L RHP and 9.7 mg/L GLGPG are shown.
aCT = cycle threshold (CT < 22 = high basal gene expression; 23 < CT < 30 = intermediate basal gene expression; CT > 30 = low basal gene expression).
bp value = significance value between (IL-1b)- and (IL-1b + substance) -treatment.
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Page 8 of 14contributing factor to OA [1]. The tested natural sub-
stances reduced its expression in macrophages and leu-
kocytes, while in chondrosarcoma cells the opposite
effect on gene expression was observed. The meaning of
this dichotomy is unclear and requires further investiga-
tion. Collectively, changes in IL-6 and TNF-a expression
by RHP and GLGPG could influence the etiology of OA
and RA. Indeed, in a recent clinical study, dietary sup-
plementation of RA patients with RHP alleviated RA
symptoms [37]. Obvious limitations in the interpretation
of the current in vitro results should be noted: (1) the
absence of data on bioavailability and pharmacokinetics
of the substances makes it difficult to correlate the
described in vitro effects with in vivo efficacy, (2) addi-
tional clinical trial to assess efficacy (anti-inflammatory
versus pain-relief) of the test substances are warranted,
(3) a possible effect of RHP and GLGPG on joint space
widening should be investigated.
The involvement of NO and PGE2 in OA has been
described in numerous studies [11,38-43]. The enhanced
production of NO in OA joints contributed to a slowly
progressing inflammation [9]. IL-1b treatment of chon-
drocytes induced iNOS and concomitant expression of
cartilage-degrading enzymes [41,42,44-46]. Conversely,
the progression of murine OA was slowed down in
iNOS knock-out mice [47]. NO also activated MMPs
[40] and PGE2 production [48] with concomitant inhibi-
tion of proteoglycan and collagen synthesis [43,49].
Chondrocyte apoptosis was promoted by NO and PGE2
[8,50-52]. In view of the observation that RHP and
GLGPG diminished NO and PGE2 production, they
might have anti-apoptotic effects in chondrocytes. The
consequence of this inhibition is pivotal, since it affects
(1) survival of chondrocytes, (2) production of pro-
inflammatory cytokines, and (3) activation of ECM-
degrading enzymes. At the molecular level, the expres-
sion of prostaglandin E2 synthase (i.e. mPGES) [53-57]
rather than COX-2 was altered by RHP (Table 2) and
therefore only weakened the production of pro-inflam-
matory prostaglandins.
MMP-1, MMP-3, MMP-13, ADAMTS-4 and
ADAMTS-5 are key catabolic enzymes that degrade
Table 6 Effect of RHP and GLGPG on gene expression in NHAC-kn cells
Gene CT
a IL-1b IL-1b + RHP (250 mg/L) IL-1b + GLGPG (9.7 mg/L)
fold change fold change p value
b fold change p value
b
MMP-1 29.5 22.8 10.4 0.008 20.0 0.418
MMP-2 23.4 0.8 0.6 0.249 0.8 0.332
MMP-3 28.1 167 89 0.048 128 0.135
MMP-9 29.6 7.2 6.0 0.025 5.0 0.203
MMP-13 28.1 2.2 1.3 0.048 2.0 0.135
ADAMTS-4 29.5 20.0 21.7 0.460 14.6 0.103
ADAMTS-5 21.7 1.3 0.9 0.011 1.7 0.148
TIMP-1 17.2 1.2 0.9 0.052 1.1 0.215
Aggrecan 28.8 1.0 0.8 0.196 1.1 0.340
Collagen 1 18.0 0.7 0.5 0.05 0.8 0.30
COL2A1 22.2 1.0 0.5 0.137 1.2 0.325
MIP-2 29.9 441 110 0.082 626 0.147
MIP-3a 30.0 481 271 0.007 436 0.126
CCL5/RANTES 26.7 87 42.0 0.009 54 0.046
IL-8 26.3 799 168 0.002 760 0.356
CXCL10/IP-10 nd
c
IL-1b 31.3 1078 530 0.002 505 0.085
IL-6 29.8 2011 1048 0.069 1927 0.226
IL-1Ra 28.4 1.2 0.6 0.107 1.2 0.272
IL-1RI 22.6 0.9 0.5 < 0.001 0.8 0.301
TNF-a nd
c
iNOS nd
c
COX-2 26.58 133 48.3 0.11 186 0.03
LIF 23.8 35.2 19.2 0.003 28.9 0.239
IL-1b -stimulated cells were cultured with 31.3 - 1000 mg/L RHP or 1.2 - 38.7 mg/L of GLGPG for 4 h and gene expression was quantified by RT-PCR. Fold
changes were calculated as indicated in Materials and Methods. Only the effects of 250 mg/L RHP and 9.7 mg/L GLGPG are shown.
aCT = cycle threshold (CT < 22 = high basal gene expression; 23 < CT < 30 = intermediate basal gene expression; CT > 30 = low basal gene expression).
bp value = significance value between (IL-1b)- and (IL-1b + substance) -treatment
cnd = not done
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Page 9 of 14collagen and proteoglycan; their sequential expression
might occur at, and herald different phases in the pro-
gression of OA [28,32,58]. Increased expression of tissue
inhibitor of matrix metalloproteinase (TIMP) is asso-
ciated with remodelling of articular tissues [59]. IL-1b
induced a high MMP-1 expression in primary chondro-
cytes, which reflects events related to early OA; SW1353
displayed a pattern of MMP expression that relates to
intermediate stages of OA. RHP and GLGPG exerted
effects only on a sub-set of these enzymes: MMP-1, -3
and -13 and ADAMTS-4. Other members of the MMP
f a m i l yt h a th a v ear o l ei nt i s s u er e m o d e l i n g( e.g.M M P -
9) [60] were not influenced by these treatments.
The impact of chemokines in OA has been substan-
tiated previously [61]: CCL5/RANTES and CXCL8/IL-8
were identified in activated chondrocytes or OA tissue
[14-16,62]. Expression levelso fc h e m o k i n e sa n dt h e i r
receptors dramatically change in IL-1b activated chon-
drocytes [7]. This emphasizes the putative role of che-
mokines in early and intermediate phases of progressing
OA. Given the described effects of RHP and GLGPG, it
is tempting to hypothesize that RHP components act as
biological modifiers on chemotaxis in OA chondrocytes.
In accordance with the in vitro study, clinical trials have
provided evidence that chemotaxis of leukocytes is
reduced after dietary supplementation with RHP [17].
Biological modulators such as IL-1b or NO eventually
activate MAPK that, in turn, leads to the translocation
of NF-B to the nucleus and NF-B dependent gene
activation. The kinetics and extent of RelA and NF-B1
expression follow similar kinetics and amplitude in IL-
1b stimulated SW1353, primary chondrocytes [28] and
RAW264.7 cells (this study). In vitro studies have
further demonstrated that this pathway was modulated
by various substances contained in the food chain
[63-68]. Regulatory motifs identified in chemokine genes
include NF-B[ 6 9 ] .D i r e c te v i d e n c et h a tR H Pa n d
GLGPG may act along this pathway is provided by the
observed down-regulation of NF-B1, NF-B49, NF-
Bp65 and - as a consequence of decreased re-synthesis
-I - Ba in activated macrophages (Table 2). The analysis
of modification of these transcription factors like phos-
phorylation is required to substantiate this hypothesis.
As previously shown [7,52,70,71], binding elements for
other transcription factors (MEF-3, AP-1 and CEBPb)
have been mapped to the regulatory region of IL-1b-o r
LPS-responsive genes [7] and might also interact with
RHP and GLGPG.
The in vitro effects described in this study were eli-
cited at high concentrations of RHP and GLGPG. To
date, no bioavailability studies have been reported for
R H P ;b u ti ti su n l i k e l yt h a tI C 50 values for RHP and its
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Figure 3 Effect of RHP and GLGPG on gene expression in chondrocytes.I L - 1 b-stimulated NHAC-kn were cultured for 4 h with 62.5 - 250
mg/L RHP or 9.7 - 38.7 mg/L of GLGPG and expression of the indicated genes was quantified by RT-PCR. Symbols on the y axis indicate the
gene expression in IL-1b stimulated NHAC-kn (relative to unstimulated NHAC-kn).
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Page 10 of 14constituent bioactive components are achieved in the
body fluids or tissues as a consequence of dietary
uptake. It is possible that after dietary intake RHP con-
stituents accumulate in peripheral blood leukocytes and
thus locally achieve threshold concentrations required
for biological effects. Assuming that GLGPG is the only
bioactive component in RHP powder, it can be deduced
from the IC50 values given in Table 1 that RHP needs to
contain ~3% of GLGPG. Yet, since the GLGPG contents
of the studied RHP preparation does not exceed 0.1% of
the dry plant mass (our unpublished results), we
hypothesize that other substances contribute to the
biological activity of RHP. The observation that sub-
stances contained in the food chain alter features of
chondrocyte biology has been documented previously:
polyphenols, including resveratrol and catechins (epigal-
locatechin-3-gallate, EGCG) reduced the expression of
MMP-1, -3 or -13 and modulated levels of iNOS and
COX-2 [63,65-68,72-74].
Conclusions
Both the onset and development of OA is expected to
be modulated by the effects of RHP and GLGPG: (1)
the observed diminished NO and IL-1b production is
likely to delay or prevent initial steps of the disease,
(2) the homeostasis of anti- and pro-inflammatory
c y t o k i n e si sa l s om o d u l a t e da n dt h u sp r o v i d e sam e a n s
to attenuate inflammatory processes in OA, and (3)
chemokines that predominantly direct the migration of
neutrophils were less abundantly produced (Table 7).
RHP and its constituents thus modulate cellular and
molecular processes that may explain the positive
effect of RHP observed in clinical trials. The effects on
interleukin and chemokine production as well as MMP
expression indicate that RHP and its constituents
down-regulate catabolic processes and reduce chemo-
taxis related to OA or RA. Collectively, the data pro-
vide a molecular and biochemical basis for the
cartilage protection by RHP.
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Figure 4 Comparison of the effects of RHP and GLGPG on murine macrophages, human PBL and chondrocytes. The symbols on the y-
axis indicate gene expression levels in stimulated cells in the absence of substances. Cells were cultured for 4 h (RAW264.7; NHAC-kn) or 2 h
(PBL).
Schwager et al. BMC Complementary and Alternative Medicine 2011, 11:105
http://www.biomedcentral.com/1472-6882/11/105
Page 11 of 14Additional material
Additional file 1: Effects of RHP and GLGPG on gene expression in
murine macrophage cell line RAW264.7. RAW264.7 cells were
stimulated with LPS and cultured with 250 mg/L RHP or 9.7 mg/L of
GLGPG for 4 h and gene expression was quantified by RT-PCR. Fold
changes were calculated as specified in Materials and Methods.
Additional file 2: Effects of RHP and GLGPG on cytokine/chemokine
production in human peripheral blood leukocytes. LPS/IFN-g
-stimulated peripheral blood leukocytes were cultured with 250 mg/L
RHP or 9.7 mg/L of GLGPG for 24 h and proteins were quantified by
multi-parametric analysis as described in Materials and Methods.
Additional file 3: Effects of RHP and GLGPG on gene expression in
human peripheral blood leukocytes. LPS/IFN-g -stimulated cells were
cultured with 250 mg/L RHP or 9.7 mg/L of GLGPG for 2 h and gene
expression was quantified by RT-PCR (for details see: Materials and
Methods).
List of abbreviations
ADAMTS: a disintegrin and metalloproteinase with thrombospondin type I
motif; GLGPG: galactolipid (2S)-1: 2-di-O-[(9Z:1 2 Z:1 5 Z)-octadeca-9: 12: 15-
trienoyl]-3-O-β-D-galactopyranosyl glycerol; IL: interleukin; LPS:
lipopolysaccharide; NO: nitric oxide; MMP: matrix metalloproteinase; OA:
osteoarthritis; PBL: peripheral blood leukocytes; PGE2: prostaglandin E2; RA:
rheumatoid arthritis; RHP: rose hip powder.
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